Establishment of HBV-sensitive human hepatocyte lines and analysis of HBV essential factors
| Project/Area Number |
18K15169
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 49060:Virology-related
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
Ueda Youki 岡山大学, 医歯薬学総合研究科, 助教 (90756074)
|
|---|
| Project Period (FY) |
2018-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | B型肝炎ウイルス(HBV) / Li23/NTCP細胞 / サブクローニング / A8.15.78.10細胞 / HepG2/NTCP細胞 / cGAS,STING経路 / 薬剤感受性 / B型肝炎ウイルス / Cyclosporin A / Rosiglitazone / Li23 / NTCP / Subcloning / HBV/secNL repoter assay / HBV / サブクローン化細胞株 / 新規宿主因子 / 新規抗HBV剤候補 |
|---|
| Outline of Final Research Achievements |
Cells derived from the human hepatoma cell line HepG2 and engineered to overexpress NTCP: a receptor for HBV, termed HepG2/NTCP cells, are widely used as the cell-based HBV infection and replication systems for HBV research. We recently found that human hepatoma cell line Li23-derived cells overexpressing NTCP (A8 cells subcloned from Li23 cells) were also sensitive to HBV infection. However, the HBV susceptibility of A8 cells was around 1/100 that of HepG2/NTCP cells. In the present study, we successfully established a Li23/NTCP-derived A8.15.78.10 cell line exhibiting high HBV susceptibility equivalent to that of the HepG2/NTCP cells widely used for HBV research. Using A8.15.78.10 and HepG2/NTCP cells, we demonstrated the necessity of plural HBV assay systems using different types of cells for the objective and impartial evaluation of anti-HBV reagents.
|
| Academic Significance and Societal Importance of the Research Achievements |
これまでのHBVの基礎研究においてはHepG2/NTCP細胞という1種類の細胞株のみを用いた研究が大半である。我々は本研究において、抗HBV剤の正当な評価には異なる細胞株を用いたHBVアッセイ系を使用することが必要であることを示した。複数のHBVアッセイ系を用いた評価がを行うことで、抗HBV活性の評価結果の信頼性が上がり、臨床応用に向けた研究の効率化が期待できる。
|
Report
(3 results)
Research Products
(26 results)
